Disclosed is a method and compounds for treating
AMPK, cGAS, or ΔF508-CFTR mediated diseases, the method including administering one or more
AMPK, cGAS, or CFTR DUBTACs to a subject who has an
AMPK, cGAS, or ΔF508-CFTR -mediated
disease, the AMPK, cGAS, or CFTR DUBTACs being heterobifunctional small-molecule compounds (or bivalent compounds in short) including an AMPK, cGAS, or CFTR ligand conjugated to a de-ubiquitination tag (such as a small-molecule ligand of USP7) via a
linker, which would stabilize AMPK, cGAS, or CFTR. The AMPK, cGAS, or ΔF508-CFTR -mediated
disease can be a
disease resulting from AMPK, cGAS, or CFTR destabilization. The AMPK, cGAS, or ΔF508-CFTR-mediated disease can have reduced AMPK, cGAS, or CFTR expression relative to a wild-type tissue of the same species and
tissue type. The disclosed bivalent compounds stabilize AMPK, cGAS, or CFTR by recruiting USP7.